The antim alarial activity of the sulfonamides was described very soon after the discovery of these drugs. As early as 1940, a num ber of papers, such as those by , Hill and Goodwin (56) , Van der Wielen (129) , 23) , Niven (83), , Menk and Mohr (81) , , Sorley and Currie (118) , Sinton et al. (117) , etc., had reported on a somewhat variable success obtained with sulfonamides in experimental and hum an malaria. For a further 10 years, i.e . until 1950, there still existed some interest in this chemical group, as reflected in some im portant clinicai trials, for instance those by Fairley et al. (36) and by Coatney et al. (16, 17) . However, w ith the advent of more reliable synthetic antim alarials, chemotherapeutic work on sulfonamides with prac^ical aims was almost dropped and rath er rem ained limited to basic questions of more theoretical interest like m echanism of action, potentiation of the effect of other a n ti malarials of the folic-acid-antagonist group on experimental m alaria, cross resistance, etc. This work is linked to renowned names such as Greenberg, Rollo, Goodwin, Bishop, Eyles and Coleman, Hitchings, etc.
Excellent cumulative reviews on sul fonamides and m alaria have been made by Curd (27) in 1943 , Findlay (42) in 1951 , and Hill (58) in 1963 It is somewhat astonishing th a t no major work was carried out during the years from 1955 to 1963, i.e . du ring the períod in which, thanks to the discovery of the so-called longacting sulfonamides , a better knowledge of the pharmacokinetics of the se drugs was obtained. It is now evident th a t m any of the early contradictory reports regarding the antim a larial effect of sulfonamides, made during the initial years of the sulfonamide era, were due to the scanty Information on the pharmacokinetics of these substances in m an and in laboratory animais, a gap which led or misled, among other things, towards empirical and therefore not quite reliable dosage.
At present, the reported resistance of certain Plasmodia strains to some major antim alarials such as pyrimetham ine, chloroquine and perhaps even quinine, and, on the other hand, the availability of some sulfones and sulfonamides w ith a very sustained action, have made it advisable to re examine the possible value of these substances as an auxiliary tool for the m anagem ent of m alaria. It is most unfortunate th a t this logical interest is hampered by the reports on cases of Stevens-Johnson and Lyell syndrome, observed during the use of some of these substances.
The purpose of this short review is to summarize: a) the available infor-mation on the effect of the sulfonamides on the different species and cycle stages of Plasmodia, b) their mechanism of action and its implications, i . e .: potentiation and resistance, and c) the trials so far carried out with the longest acting sulfonamide sulformetoxine, Ro 4-4393 *.
As it can be seen from Tables I to IV, the effect of the sulfonamides has been tested on the blood schizonts in most of the laboratory anim al Plas modia. They are considerably active against the blood schizonts of P. berghei, P. gallinaceum, P. knowlesi and P. falcipam m and less or not ac tive in the rest. The results obtained in cases of spontaneous or induced falciparum m alaria have been almost unanimously positive although the onset of action of the sulfonamides is slower th an th a t of the major antim alarials. This has precluded their use in the treatm ent of acute m ala ria. The results reported on m alaria due to P. vivax are less uniform . So me authors find them to be effective here (although always less so th a n in P. falciparum), whereas others (35, 36, 51, 81, 93, 106) find practically no therapeutic activity. This may have been due to differences in the dosage or to the fact th a t the effects of dif ferent sulfonamides vary considera bly (42). Very few investigations have been carried out with sulfona mides in cases of malariae and ovale m alaria.
Sulfonamides have a definite cau sai prophylactic effect against certain Plasmodia such as P. knowlesi and P. gallinaceum (Table I I ) . Regarding hum an m alaria, the reports are rather scanty, but it seems th a t sul fonamides, at the doses tested, do not act as causai prophylactics (16, 17) .
The sulfonamides do not exert any effect on the gametocytes of the h u man types of m alaria (Table I I I ) . In fact, they can even increase their number in the blood (41). Fairley et al. in 1945 and Findlay et al. in 1946 reported th a t sulfamezathine rendered the gametocytes of P. falciparum incapable of developing in the mosquito (Table IV ) . However, Laing in his recent studies did not find such an effect w ith Fanasil (70) . F u rth er research on this subject is therefore needed. There is no inform ation which would allow the assumption th a t sulfonamides possess any activity as secondary tissue schizonticides in hum an m alaria. According to Bishop, exo-erythrocytic pa rasites are "relatively insensitive" to proguanil and sulfadiazine (7).
Mode of action of sulfonamides in m alaria: It is paradoxical th a t the mechanism of action of sulfonamffles, although not in ali its details, is better known th a n th a t of most major antim alarials. Since the initial work by Maier and Riley (76) , who proved in 1942 th a t the antim alarial effect of the sulfonamides is antagonized by paminobenzoic acid, a num ber of stu dies have been carried out, mainly by Greenberg, Goodwin, Rollo, Bishop, Hitchings, Thurston, etc. (6, 47, 49, 50, 59, 60, 101, 102, 127) . Sulfonami des, biguanides and pyrimethamine constitute the group of the so-called folic-acid-antagonist antim alarials, i. e. "those antim alarials whose ac tion has been considered to be concerned with interference with the synthesis of purines and pyrimidines via the PAB ■> folie acid * folinic acid system" (102). According to Rollo (Fig. 1) , sulfonamides probably act on reaction A by simple metabolite competition, whereas biguanides and pyrim etham ine act in a more complicated m anner on reaction B. These analogies and differences between the mechanism of action of sulfonamides on the one hand and of the biguani des and pyrim etham ine on the other entail a complex framework of possible reciprocai effects when two of the se drugs are given together (poten tiation) or in succession (cross resista n c e ).
The possibility of cross resistance has been dealt w ith in several recent Sulfonam ide-resistant strains of some species of Plasmodia (e .g. P. gallinaceum) are usually also resistant to proguanil and pyrim etham ine (7, 101) . Strains resistant to pyrimethamine and proguanil or its triazine derivative are generally not or only partially resistant to sulfo namides (85, 98, 101, 113, 115, 122, 126) . DDS-resistant strains are usually resistant to sulfonamides (8, 87-88, 90, 122) . Usually there is no cross resistan ce between sulfonamides or sulfones and antim alarials not belonging to the group of the folicacid-antagonists. Frequently the re is even some hypersensitivity (55, 63, 84-88, 91, 120, 122) . reviews (7, 58, (107) (108) (109) . Fig. 2 to 9 1) are a poor attem pt to represent graphically the m ain observation of cross or coincidental resistance in ex perimental m alaria due to Plasmodia berghei, gallinaceum, cynomolgi and 2) knowlesi th a t have been reported. These figures make no claim to being complete or perfect since I may have . missed some valuable reports. On the other hand, there are some minor discrepancies in the literature, undoubtedly due to differences in the 3) techniques used for creating resistan ce and to the inevitable differences among the strains. 4) Nevertheless, w ith regard to any possible clinicai application of sulfo namides (alone or combíned with pyrimethamine) the m ost im portant facts about experimental cross resis tance are: Now to potentiation. The fact th a t sulfadiazine and other p-aminobenzoic competitors with antim alarial activity . are able to potentiate the action of proguanil against blood schizonts of P. gallinaceum has been known since the work by Greenberg in 1949 (47, 49-50) . Proguanil and pyrimethamine do not potentiate each other (101). Later on, it was proved th a t the same applies if the sulfonamide is replaced by a sulfone an d /o r if pro guanil is replaced by pyrim etham ine (4-5, 101). A similar potentiation has in the meantime also been confirmed in experimental and hum an toxoplasmosis (34, 44, 59) . In m alaria, however, there had u n til 1963 been only a few tentative attem pts to test the potentiating effect between sul fonamides and pyrim etham ine in man (Hurly in 1959 (62); McGregor, Williams and Goodwin in 1963, (80) .
In 1964, DeGowin and Powell (30) showed th a t 2,0 g sulfadiazine daily for 5 days gíven concurrently with 50 mg pyrim ethamine daily for 3 days cured 5 out of 6 volunteers infected with the Malaya (Camp) strain of P. falciparum resistant to chloroquine, hydroxy-chloroquine, quinacrine, chlorguanide, and pyrimethamine. Previous trials with the same doses of sulfadiazine and pyrim etham ine given separately had not been successful.
One m onth later, in December 1964, Laing (67) reported on the first resuits of his study of the antim alarial effect of Fanasil (Ro 4-4393). This sulfonamide shows the longest period of elimination ever described in m an. It has a half-life of 100 to 200 hours. (Sulfadiazine: 17 h o u rs ). This permits therapeutically sufficient blood leveis to be m aintained by weekly adm inistration of low doses, either orally or p arenterally. The slow elimina tion is not due to any intentional conventional modification of the basic molecule (e. g. N, -acetylation) or to the pharm aceutical píesentation (e. g. repository injection or late release ta b le t), but to the intrinsic structure of the basic molecule itself. Oral absorption of Fanasil is as rapid as th a t of the usual sulfonamides. These two properties, rapid absorp tion and slow elimination, together with the good activity it has shown in the usual chem otherapeutic experi m ental tests (96, 128) , have justified extensive clinicai trials w ith the subs tance in the common indications of the sulfonamides (1, 25, 64) , with es pecial attention to those in which single-dose treatm en t (e.g . meningococcal meningitis in epidemic developing countries (39) and long-term treatm ents e .g . leprosy (3), trachom a (40), systemic mycoses (74) are most indicated.
On the basis of the experience gained during clinicai trials in the tre a t m ent of about 15,000 cases (some 100 of them treated continuously for several years) it can be stated th a t the tolerance of Fanasil is a t least as good as th a t of the most highly reputed sulfonamides. The possibility of oral weekly adm inistration makes Fanasil quite suitable for combined treatm ent with pyrim etham ine.
The activity of Fanasil in experi m ental m alaria has been studied by Richards (94) ( Table V ) . Fanasil showed good antim alarial activity and a m arked potentiation with pyrime tham ine against sensitive strains as well as against strains of P. gallina ceum and P. berghei resistant to py r i m e t h a m in e , triazine or chloroquin e . T h e pyrim etham ine-resistant strain of P. gallinaceum was some w hat less sensitive to the potentiating m ixture (pyrim etham ine + Fanasil) th a n the norm al strain . However, the resistance factor was only 2 to 5, as compared with > 300 for pyrim etha mine alone.
These results have been confirmed in their m ain lines by Brener (9). The optimum potentiating ratio in these chem otherapeutic studies seems to be in the region of 10: 1 (Fa nasil: pyrim etham ine) bu t the ran ge appears to be very broad. Prophylactic single-dose treatm ent showed th a t Fanasil has the most prolonged activity among other long-acting sul fonamides and DDS. Fanasil (20 m g/kg x 7) and F ana sil -pyrim ethamine (2.6 mg kg -j-0.004 m g/kg x 7) were also effective against infection produced by P. gal linaceum sporozoites. Treated chicks remained free from parasites for the duration of the experiment (35 days of observation), whereas the Controls died within 17 days (94) . It seerns therefore th a t there may also be a potentiation of the causai prophylactic effect.
Treatm ent of acute malaria with Fanasil alone or combined with pyri methamine : a) P. falciparum '. Laing (68, 71, 72) , working in Amani, Tanzania, i.e . in an area where pyri methamine resistance is known to occur, has reported the following results: A total of 105 "semi-immune" B antu Africans seeking tre a t ment for fever were treated with one dose of Fanasil (1 g) alone (45 cases) or with one dose of 500 mg Fanasil in combination with 12.5 mg pyrim etham ine (45 cases) or with one dose of chloroquine (200 mg i.m . or 600 mg orally) (15 cases) and thereafter a diagnosis of acute falciparum m alaria was made by means of parasite counts from thick blood films. The results are shown in Table VI. In the group receiving Fanasil + pyrim ethamine, asexual parasitem ia was cleared in 88% of the patients w ithin 48 hours compared to only 30% in the group receiving Fanasil alo ne. In another experience, two small children who had not responded to 50 mg DDS did respond to 250 mg Fanasil alone (69) .
In an unpublished study carried out recently in M alaya. Laing (72) tried Fanasil alone or with pyrim etham ine in 62 "semi-immune" patients suffering from acute m alaria due to P. falciparum . The results are shown in Table VII . The treat m ent was considered to be a failure in those cases where asexual parasitem ia was present on the seventh day of observation or where therapeutic intervention with another antim alarial drug was necessary in the interest of the patient. After a single dose of 1 g Fanasil given to 9 indivi duais there was one failure. Clearance of asexual parasitem ia was somewhat slower th a n in African patients (average 3.1 days com pared with 2.3 d a y s). Various combinations of Fanasil (200 mg to 1 g) with pyrim etham ine (25 to 50 mg) gave similar results in 53 patients (6 failures) with an average duration of parasite mia of 2.2 days. Among the few patients receiving the highest dose of 1 g Fanasil -I-50 mg py rim etham ine there were no failures. 4 patients who had early recrudescences of parasitemia and febrile symptoms after treat m ent with chloroquine (1.5 -2.0 g orally over 3 to 4 days in 3 adults and 0.280 g parenterally in a two year old girl) were also treated with a single dose of Fanasil + pyrim etham ine (1 g Fanasil + 25 mg pyrim etham i ne for the adults and 250 mg Fanasil + 6,25 mg pyrim etham i ne for the ch ild ); three of the patients were "apparently cured" and one (an adult) to whom py rim etham ine was given 3 days prior to Fanasil showed no res ponse to the dose of pyrim etha mine, whereas after Fanasil scanty asexual parasitem ia persisted for 7 days. Among 36 pa tients treated with 600 to 2,500 mg chloroquine there were 11 failures .
In Bangkok, H arinasuta (52) gave Fanasil alone or in combi nation w ith pyrim etham ine or chloroquine to 66 patients (adul ts) w ith recrudescences after chloroquine-resistant acute P . falciparum m a la ria . The preli- * except for chloroquine ** with a follow-up of less than 28 days C.T.E. = complete temporary effect (clearance of asexual parasitemia with subsequent relapse) P.T.E. * partial temporary effect (reduction not abolition of asexual parasitemia) m inary results are shown in Ta ble VIII. On the basis of clinicai response and duration of parasitemia, the best results were obtained w ith the following combinations: A) 1 g Fanasil (sin gle dose) + 1.5 g chloroquine in three d ay s); B) 0.5 g Fana sil + 25 mg pyrim etham ine in a single dose. The latter has the practical advantage of being a one-dose th e ra p y . Since dura tion of parasitem ia is longer th a n th a t seen after chloroquine in chloroquine-sensi,tive cases, further trials are being carried out with higher doses of the combi nation Fanasil + pyrim etha mine.
Sensitivity to chemotherapy of seven strains of P. falciparum found in four Brazilian regions, in patients who did not respond satisfactorily to chloroquine, was studied by Lopes and Rodrigues da Silva (75) in 25 neurosyphilitic patient with blood-induced m alaria. Ali seven strains show ed resistance to the standard "field-te st" dose (10 m e /k e of chloroquine recomended by WHO for prelim inary selection of susp e c t e d chloroquine-resistant s tra in s ). Three of the seven strains turned out to be only partially chloroquine -resistant, since parasitem ia disappeared after a higher dose of chloroqui ne (3 g in 3 days). The other four strains were considered as fully resistant to chloroquine; two of them were also resistant to pyri methamine, and a t least partial ly, to quinine. These two last strains (PoL , and Po::), i. e., those fully or partially resistant to the three above mentioned major an timalarials, were sensitive to Fa nasil combined with pyrim etha mine. As shown in Table IX , the therapeutic response (8 cases), however, took place rath er slowly. Clinicai response was achieved in 4 to 8 days, the trophozoites disappeared from the blood in 4 to 6 days and the gametocy tes in about a m onth.
Almeida, Brazil, (2) has repor ted on the preliminary results of an extensive study being carried out in cases of spontaneous ma laria. The patients are followed up for 6 days after receiving one of the three following treatm ents: Group A) 10 m g/kg chloroquine, 5 days later 10 mg kg chloroquine and 5 mg kg chloroquine on each of the 2 following days (total dose 30 mg/ kg in 8 d a y s). Group B) 40 m g/kg chloroquine in 4 days. Group C) 1 g Fanasil and 50 mg pyrim etham ine on the first day and 0,5 g Fanasil on the follow ing day. According to the preli m inary results (197 courses of treatm ent in 178 patients fol lowed), some cases of the groups A and B have shown recrudescences during the follow-up period. In the group C (14 cases already observed over 60 days) 4 cases became negative during the first day of treatm ent and the other 10 cases during the second o n e. Ali of them remained negative over the followup period.
Peringle and Lane (89), Tan zania, have reported on the re sults obtained with 250 mg Fa nasil in 9 schoolchildren who developed one or tw o clinicai fits of falciparum m alaria three to six m onths after the injection of the repository antim ala rials cycloguanil pamoate, or DADDS, or both (Table X) . Bv the fourth day after the dose of Fanasil trophozoites had disap peared from the blood in ali cases. b) P. vivax. Confirming the results obtained by previous workers with older sulfonamides, Laing in Malaya also found P. vivax to be less sensitive to Fanasil than P. falciparum (Table VII) In the same holoendemic area in N ortheastern Tanzania, Pringle and Lane (89) had the opportunity of testing the sup pressive effect of Fanasil and Dapsone on break-through parasitemias among children previously injected with one of the above mentioned repository antim alarial agents. These substances had been administered during a drug trial conducted 5 m onths previously. As shown iin Table X II a single dose of 100 mg Fanasil was first given to patients of the biguanide and sulfone groups. O ut of 34 trophozoite carriers, only two had scanty parasitem ia one week later, whereas 13 were again po sitive after one m onth. At th a t time the patients of these two groups received one 100 mg dose of Dapsone which failed to suppress parasitem ia in 2 cases. Two and a half m onths later, the three groups (biguanide, sulfone and combined) were gi ven either 100 mg Fanasil (68 patients) or 100 mg Dapsone (54 p a tie n ts). Fifty days later the same patients received 50 mg Fanasil or Dapsone. From the overall results it appears th a t Fanasil was the more ef fective drug in suppressing such break-through parasitemias.
Shute and Dowling (110) compared the suppressive action of Fanasil and chloroquine on pa rasitem ia in schoolchildren li ving in the W estern region of Ni géria where m alaria is holoen demic . As shown in Table XIII , the children of each of three large schools received one of the following drug regimens: F an a sil 500 mg once a week for 4 weeks, Fanasil 500 mg as a sin gle dose, or chloroquine 300 mg as a single dose. No treatm ent was given in two smaller schools where the children were considered as Controls. Blood surveys (thick blood films) were carried out before th e beginning of the trials and a t weekly intervals for 4 weeks thereafter. The untreated Controls showed continuing falciparum parasite mia in 69 to 81% of the cases throughout the trial. Both regimens of Fanasil were found to be highly effective against ase xual P. falciparum parasitem ia as from the first week when ali cases were negative. In the F a nasil groups, the highest incidence of children with trophozoites was 2% after 4 weeks (in the single dose group), whereas in the chloroquine group the incidence of positive cases was 5 '/ after one week and progressively increasing to 16% after 4 weeks. b) P. malariae. Shute and Dowling (110) also registered quite a high pre-treatm ent incidence of asexual parasitem ia due to P . malariae during the surveys in the above mentioned Nigerian schools. The rates of positive cases before and after treatm ent are given on the extreme right of Table X III which shows a rate of 10 to 15 % prior to treatm ent, increasing to 19Çv after 4 weeks in the control group. This ta ble also shows th a t the effect of chloroquine on P. malariae was entirely satisfactory and th a t both regimens of Fanasil were almost as effective as chloro quine . Recent (unpublished) work carried out in Indonésia (61) Gametocytocidal effect: According to the findings reported by Shute and Dowling (110) and by Laing (66, 72) , Fanasil has actually no gametocyto cidal effects, the slow disapearance of sexual forms of P. falcivarum being the result M the schizonticidal action of the drug.
Effect on sporogony:
Investigations were carried out by Laing (70, 72) to determine the effect of Fanasil alone and combined with pyrim ethamine on falciparum sporogony. Batches of laboratory-bred Anopheles gambiae were fed on patients with sexual pa rasitem ia after tre a m e n t. Ali surviving mosquitoes were negative after having fed on 2 patients previously treated with 500 mg Fanasil + 12.5 mg pyrim etham ine. The same result was obtained in a further 2 patients after the combination of 500 mg Fa nasil and 6.25 mg pyrim etham ine. However, when a 1 g dose of Fanasil alone was given to a patient on two occasions, a significant num ber of mosquitoes were found to be positive after each dose. Consequently Fa nasil alone does not seem to affect norm al falcivarum sporogony in mos quitoes. W hen given together with a small dose of pyrim etham ine, which may be insufficient in itself, there appears to be potentiation of the spo rontocidal effect of the latter. In ex perim ental m alaria (P. gallinaceum) such a potentiation has already been described by R am akrishnan et al. (91) for DDS, although given by it self this substance did not show any sporontocidal effect.
Effect of P anas11 and chloroquine on asexual parasitemia in African schoolchildren of 6 to 14 years (control group 6 to 11 years) (Shute and Dowling,Nigeria ) 
S U M M A R Y
R eview of th e ea rly lite ra tu re a s w ell as m ore re c e n t resu lts sh ow th a t su lfo n a m id es possess a d is tin c t a n tim a la r ia l a c tiv ity . H ow ever, w h e n give alone, th e ir a ctio n is less m a rk e ã a n ã slo w er th a n th a t o f th e a n tim a la ria ls co m m o n ly u sed in th e tr e a tm e n t of th e a cu te a tta c k . C o m b in a tio n s w ith p y r im e th a m in e p ro v iá e b e tte r resu lts, even in cases of p y r im e th a m in e an ã ch loroqu in e resistan ce. T his w a rra n ts fu r th e r in v e stig a tio n s in an a tte m p t to ã ev elo p a th e ra p e u tic a g e n t su ita b le fo r th e tr e a tm e n t of such re s is ta n t ca ses. I t m a y also be p o ssib le w ith an a p p ro p ria te co m b in a tio n of p y r im e th a m in e w ith a su lfo n a m id e to a c h ie v e a s a tis fa c to r y m e th o d fo r su p p ressive tr e a tm e n t b o th in a rea s w ith a n d w ith o u t p y r im e th a m in e r e s is ta n c e . A lth o u g h its a ctio n is slo w er th a n th a t o f 4-am in oqu in olin es, i t m a y be u sefu l as a seco n d ch oice dru g in se m i-im m u n e su b je c ts fo r th e th e r a p y o f falciparum m a la ria . P relim in a ry re su lts sh ow th a t, w h en c o m b in e d w ith p y r im e th a m in e , F an asil is h ig h ly c ffe c tiv e in su p p ressin g fe v e r a n d asexu al p a ra site m ia due to P . falciparum . S ingle doses of 1 g F an asil to g e th e r w ith 50 m g p y r im e th a m in e seem to be a d eq u a te fo r th e tr e a tm e n t of a cu te falciparum m a la ria in se m i-im m u n e p a tie n ts . T h e o n set of a c tio n of th e co m b in a tio n is m u ch m ore ra p id th a n th a t of th e sin gle c o m p o n e n ts. W eek ly doses of 500 m g F an asil a n d 25 m g p y r im e th a m in e a p p ea r to p ro v id e s a tisfa c to ry su p p ressive e ffe c ts a g a in st P . falciparum a t le a st in E a st A fric a . T h is co m b in a tio n is a c tiv e on str a in s w h ic h do n o t re sp o n d s a tis fa c to r ily to th e s ta n d a r d doses o f p y r im e th a m in e a n d /o r ch lo ro qu in e a n d seem s to h a ve a s a tis fa c to r y sp o ro n to c id a l e ffe c t.
P relim in a ry re su lts in d ic a te th a t F an asil alon e c a n n o t be reco m m en d ed for use a g a in st th e o th e r h u m an m a la ria p a ra site s. T he co m b in a tio n w ith p y rim e th a m in e a p p ea rs to be m u ch m o re e ffe c tiv e . E a st A frica n stra in s of P. m alariae seem to re sp o n d b e tte r to th e co m b in a tio n th a n do M alayan stra in s o f P. vivax b u t fu r th e r tria ls are req u ired b efo re d e fin ite a sse ssm e n t ca n b e m a d e .
F an asil b y its e lf h a s n o g a m e to c y to c id a l or sp o ro n to c id a l a ctio n b u t seem s to p o te n tia te th e effect of p y r im e th a m in e a t le a st on sp orogon y of P. falciparum . 
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